Blood Test Could Forecast Dementia Risk in Women Up to 25 Years Early

Blood test for Alzheimer’s-related protein may predict dementia risk decades before symptoms

Overview of the finding

A recent study reports that a blood test measuring a specific phosphorylated form of the tau protein, known as p-tau217, can be associated with an increased risk of developing mild cognitive impairment (MCI) or dementia in older women as early as 25 years before symptoms appear. The research adds to growing evidence that blood-based biomarkers offer a less invasive, more accessible route to identifying Alzheimer’s-related brain changes compared with traditional methods such as expensive brain imaging or cerebrospinal fluid (CSF) analysis.

Why p-tau217 matters

Alzheimer’s disease is characterized in part by abnormal accumulations of tau protein in the brain. When tau becomes phosphorylated — that is, when phosphate groups attach to the protein — it can form variants collectively referred to as phosphorylated tau (p-tau). Several p-tau species circulate at detectable levels in blood plasma. Accumulating research from tightly controlled clinical settings has indicated that plasma p-tau217 levels are elevated in people with Alzheimer’s disease and can help predict future dementia risk. This new study extends those observations into a cohort of older women observed over long time frames.

Details and significance of the new study

What the researchers measured

The investigators measured plasma p-tau217 and examined its relationship with subsequent diagnosis of MCI or dementia. The key takeaway is that elevated p-tau217 levels correlated with higher risk of developing cognitive impairment many years later — in some cases up to 25 years before clinical symptoms were evident. That long lead time is important because it suggests a window during which interventions and preventive measures could be considered.

Why blood-based biomarkers could change practice

Blood tests are simpler to administer, less costly, and more scalable than amyloid or tau PET scans and lumbar puncture procedures for CSF sampling. If validated and implemented responsibly, a blood-based p-tau217 assay could increase access to biological risk information for larger and more diverse populations, enabling earlier monitoring and potential risk-reduction strategies without relying solely on specialized centers.

How age, race, and genetics affected results

Variation in the association

The study also examined how demographic and genetic factors influenced the link between p-tau217 and later dementia risk. Findings indicated that age, race, and genetic predisposition modified the strength of the association, underscoring that biomarker interpretation may need to be contextualized for individual characteristics. These differences highlight the importance of evaluating biomarkers in diverse, real-world cohorts rather than relying exclusively on tightly controlled clinical-trial populations.

Expert perspective and practical implications

Independent expert commentary

Ian McDonough, PhD, an associate professor at the State University of New York at Binghamton who was not involved in the study, described the results as showing that p-tau217 has “good (but not great) predictability of all-cause dementia/MCI.” He noted the inherent challenge of making long-range predictions: the farther out one tries to predict, the more uncertainty increases. McDonough emphasized the potential public-health value of earlier risk identification, pointing out that knowing one’s elevated risk earlier in life could allow time to make lifestyle changes — such as improving sleep, reducing stress, increasing exercise, and enhancing cognitive and social engagement — that may help reduce subsequent dementia risk. His comments were provided to medichelpline.

What this means for individuals and clinicians

For clinicians and patients, a reliable blood marker that signals elevated risk long before symptoms arise could inform monitoring strategies and shared decision-making. However, the predictive power is not absolute. Elevated p-tau217 increases the likelihood of future cognitive decline but does not guarantee it; conversely, normal levels do not rule out later disease. Clinicians would need to integrate biomarker results with clinical assessments, family history, and other risk factors when advising patients.

Strengths, limitations, and next steps

Strengths of the research

A major strength of this study is its application in an older-woman cohort observed over extended periods, providing insight into how p-tau217 behaves outside tightly controlled trial conditions. That real-world perspective helps move the field toward broader clinical utility and equitable implementation across diverse populations.

Considerations and remaining questions

While promising, the findings also underscore limits: the predictive ability of p-tau217 is meaningful but imperfect, and demographic and genetic modifiers require further study. The study does not imply that a single blood test is determinative; rather, it positions p-tau217 as a potentially useful component of a multifactorial assessment of dementia risk. Additional research will be needed to refine thresholds, understand population-specific performance, and determine how best to combine p-tau217 with other biomarkers and risk modifiers in clinical practice.

Conclusion

This study strengthens evidence that plasma p-tau217 is associated with future risk of MCI and dementia and that this association can be detected decades before clinical onset in older women. By demonstrating how factors such as age, race, and genetics shape that association in a real-world sample, the research moves the field closer to practical, scalable risk assessment tools. At the same time, experts caution that p-tau217’s predictive power is not definitive, and any clinical use should be integrated with comprehensive risk evaluation and guidance on preventive strategies.